United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution, 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years). brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with brimonidine tartrate ophthalmic solution 0.15%,1 drop in both eyes three

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals limited - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution, 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years). brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with brimonidine tartrate ophthalmic solution 0.15%,1 drop in both eyes three

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - brimonidine tartrate 2 mg/ml;   - eye drops, solution - 0.2% w/v - active: brimonidine tartrate 2 mg/ml   excipient: benzalkonium chloride citric acid polyvinyl alcohol purified water sodium chloride sodium citrate dihydrate sodium hydroxide

Canada - English - Health Canada

pharmascience inc - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

Canada - English - Health Canada

hikma canada limited - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 5 mg in 1 g - mirvaso (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. mirvaso topical gel is contratindicated in patients who have experienced a hypersensitivity reaction to any component. reactions have included angioedema, urticaria, and contact dermatitis [see warnings and precautions (5.6) and adverse reactions (6.1,6.2) ]. pregnancy category b. there are no adequate and well-controlled studies of mirvaso topical gel in pregnant women. in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. mirvaso topical gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. brimonidine tartrate was not teratogenic when given at oral doses up to 2.5 mg/kg/day in pregnant rats during gestation days 6 through 15 and 5 mg/kg/day in pregnant rabbits during gestation days 6 through 18. it is not

New Zealand - English - Medsafe (Medicines Safety Authority)

miro healthcare limited - brimonidine tartrate 2 mg/ml; timolol maleate 6.8 mg/ml equivalent to timolol 5mg/ml - eye drops, solution - active: brimonidine tartrate 2 mg/ml timolol maleate 6.8 mg/ml equivalent to timolol 5mg/ml excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate hydrochloric acid monobasic sodium phosphate monohydrate sodium hydroxide water for injection - brimonidine timolol indoco is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension not adequately responding to monotherapy.

Canada - English - Health Canada

pharmascience inc - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

Canada - English - Health Canada

dominion pharmacal - brimonidine tartrate - solution - 0.2% - brimonidine tartrate 0.2% - alpha-adrenergic agonists

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - brimonidine tartrate 2 mg/ml - eq. brimonidine 1,3 mg/ml; timolol maleate 6,8 mg/ml - eq. timolol 5 mg/ml - eye drops, solution - 2 mg/ml - 5 mg/ml - brimonidine tartrate 2 mg/ml; timolol maleate 6.8 mg/ml - timolol